- 0208 903 4819
- Weekday Hours: 10AM - 5PM
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in adipose
tissue. This may throw off the hormone balance and lower fertility rates. According to studies, 12% to 15%
of couples who struggle with infertility that engage in unprotected sex after a year are still unable to
conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in adipose tissue. This may throw off the hormone balance and lower fertility rates. According to studies, 12% to 15% of couples who struggle with infertility that engage in unprotected sex after a year are still unable to conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Infertility and weight gain are linked with weight being a factor for infertility.
Wegovy aids in weight loss and therefore would help improve pregnancy
outcomes. After the doctor reviews the patient in a consultation, it will
determine if the patient is suitable to use the medication. The patient would
start on the starter dose of 0.25mg if approved for Wegovy.
Infertility and weight gain are linked with weight being a factor for infertility. Wegovy aids in weight loss and therefore would help improve pregnancy outcomes. After the doctor reviews the patient in a consultation, it will determine if the patient is suitable to use the medication. The patient would start on the starter dose of 0.25mg if approved for Wegovy.
Semaglutide, a medication for type 2 diabetes, is marketed under the name Wegovy. Semaglutide are members of the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. These drugs imitate the functions of the GLP-1 hormone, which aids in controlling body weight, food consumption, and hunger. By slowing down the time it takes to digest the food consumed, it makes the person feel fuller for longer which in turn reduces food intake. This accompanied with a healthy lifestyle will lead to successful weight loss outcomes.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months,dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Before recommending Wegovy for weight control, medical professionals will evaluate a number of aspects, including general health and BMI. If the patient meets the eligibility requirements and the medicine is deemed appropriate for managing their weight, they can be prescribed Wegovy. There maybe a few factors preventing the prescribing of Wegovy such as Thyroid cancer or any medical conditions which could be a health risk. The patient must be reviewed by a healthcare professional to be reviewed for the suitability of the medication.
Read our articles on Wegovy & Mounjaro if you would like to learn more about the benefits, the research and case studies.
Videos created by our chief doctor on managing and understanding Wegovy to help you achieve the best outcomes possible.
Book an Appointment Today
All consultations and prescriptions are carried out by GMC registered medical practitioners.
All dispensing and shipping of medicines are completed by a UK licensed, GPhC registered Pharmacy no: 9011284.
CloudRx is our partner pharmacy and prescribing service.
*Disclaimer: Results may vary from person to person depending on individual engagement and commitment to the programme.
The content of this website is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice. Do not use the information on this website for diagnosing or treating any medical or health related condition. If you have or suspect you have a medical problem, promptly contact your healthcare provider.
© 2023 The London Obesity Clinic
